Bleeding Disorders
From the Journals
Bleeding disorders don’t carry increased risks for patients undergoing endoscopy
Findings from a retrospective study of 48 patients with bleeding disorders suggests that there is not a greater risk of bleeding when undergoing...
From the Journals
Erectile dysfunction appears prevalent with hemophilia
A survey of men with hemophilia reveals that erectile dysfunction may be fairly common with the bleeding disorder and that its prevalence...
From the Journals
FXIII replacement may improve hemostasis in acquired hemophilia A
The researchers found that measuring Factor XIII levels was useful in helping control hemostasis.
From the Journals
Von Willebrand disease screening is low prior to hysterectomy
The level of screening – less than 1% – is out of alignment with current recommendations that call for consideration of underlying bleeding...
Conference Coverage
Gene therapy in hemophilia is just version 1.0
PRAGUE – The biggest question for gene therapy today is durability, according to Dr. John Pasi.
Conference Coverage
Think duration, not dose, when managing bleeding with non–factor replacements
PRAGUE – The duration of treatment is more strongly linked to thromboembolism than dose magnitude, according to Dr. Andreas Tiede.
Conference Coverage
Emicizumab performs well in surgical setting
PRAGUE – Based on the experience in this small study, bleeding complications were most common during dental procedures.
Conference Coverage
Subcutaneous FVIIa marzeptacog alfa reduced bleeding days
PRAGUE – The treatment was well tolerated with no reports of thrombosis or antidrug antibodies detected.
Conference Coverage
Padua variant factor IX gene shines in AMT-061
PRAGUE – Early data shows clinically meaningful factor IX activity in men with hemophilia B.
News
FDA approves turoctocog alfa pegol for hemophilia A
The product won’t be available before 2020.
Conference Coverage
Fitusiran is reversible during dosing suspension
PRAGUE – Temporary suspension of a phase 2 trial of fitusiran offered a chance to study the reversibility of the antithrombin agent.